Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients. (9th April 2022)

• Record Type: Journal Article
• Authors: Lv, Jialing; Zhang, Wen; Deng, Ruoyu; Chen, Yanqiong; Liu, Meiyan; Zhang, Zhijun; Wang, Qing; He, Yongmei; Liu, Yaling; Wang, Fengting; Lv, Zengbo; Zhou, Huahua; Li, Chongxin; Zhang, Tengfei; Fu, Yanyan; Zhao, Xingqiang; Bao, Qiuping; Miao, Yi; Wang, Lin; Huang, Meifang; Zhang, Chao
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 47:Number 8(2022)
• Page Start: 1257
• Page End: 1263
• Publication Date: 2022-04-09
• Subjects: camrelizumab -- chemotherapy -- efficacy -- non‐small cell lung cancer -- safety; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.13664
• Languages: English
• ISSNs: 0269-4727

Abstract

Abstract: What is known and objective: Camrelizumab is a recently developed PD‐1 inhibitor in China applied in treating different cancers including lung cancer. This study is designed to evaluate the efficacy, safety and prognostic factors for camrelizumab plus carboplatin and pemetrexed (CP) chemotherapy in treating patients with advanced lung adenocarcinoma. Methods: Of 51 advanced lung adenocarcinoma patients with negative driver genes who received camrelizumab plus CP chemotherapy were recruited. These patients received four cycles of camrelizumab plus CP chemotherapy in a 21‐day cycle. Then, camrelizumab, pemetrexed or camrelizumab plus pemetrexed was administered as maintenance therapy. Results and discussion: The rates of complete response, partial response, stable disease and progressive disease were 2.0%, 56.8%, 19.6% and 5.9%, respectively; while treatment response of 15.7% of patients was missing or not evaluable. The objective response and disease control rates were 58.8% and 78.4%, respectively. With a median follow‐up period of 14.9 months (the follow‐up duration ranged from 3.9 months to 24.3 months), 41 (83.4%) cases of disease progression and 22 (43.1%) cases of death were recorded. The median progression‐free survival (PFS) was 10.5 months (95% confidence interval (CI): 8.4–12.6 months) with a 1‐year PFS rate of 36.3% and a 2‐year PFS rate of 7.5%. In addition, the median overall survival (OS) was 18.7 months (95% CI: 16.4–21.0 months) with a 1‐year OS rate of 79.1% and a 2‐year OS rate of 30.4%. In consideration of safety, the most frequent adverse events were peripheral neuropathy (37.3%), neutropenia (37.3%), alopecia (35.3%), etc. and most of them were grade 1–2 and could be controlled. What is new and Conclusion: Camrelizumab plus CP chemotherapy achieves favourable efficacy and tolerable adverse events in advanced lung adenocarcinoma patients. Abstract : Of 51 advanced lung adenocarcinoma patients with negative driver genes who received camrelizumab plus CP chemotherapy were recruited. Patients received 4 cycles of camrelizumab plus CP chemotherapy in a 21‐day cycle. Then, camrelizumab, pemetrexed or camrelizumab plus pemetrexed was administered as maintenance therapy. The ORR and DCR were 58.8% and 78.4%, separately. The median PFS was 10.5 months (95%CI: 8.4–12.6 months) with 1‐year PFS rate of 36.3% and 2‐year PFS rate of 7.5%. Moreover, the median OS was 18.7 months (95%CI: 16.4–21.0 months) with 1‐year OS rate of 79.1% and 2‐year OS rate of 30.4%. Regarding safety, the commonly observed adverse events were mild and manageable.